research A frameshift mutation in HTRA1 expands CARASIL syndrome and peripheral small arterial disease to the Chinese population
A new genetic mutation linked to CARASIL syndrome and small artery disease was found in a Chinese family.
Search
for
Sort by
Research
120-150 / 1000+ results
research STRIAA (Severity TRichoscopy Index Alopecia Areata): Validation of a Novel Trichoscopic Tool for Evaluation of Alopecia Areata
The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study
5ARI treatment improves hair growth in older men with minimal side effects.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
research 218 Chemokine receptor CCR5 is the novel target for the treatment of alopecia areata
Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
research Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
research Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population
Longer TA repeats in the SRD5A2 gene may increase acne risk in Chinese people.
research Advanced Platelet-Rich Fibrin Plus (A-PRF+) as an Additive to Hard Tissue Managing Protocols in Oral Surgery: A Systematic Review
A-PRF+ improves bone healing and stability in oral surgery.
research The Androgen Receptor and Its Use in Biological Assays: Looking Toward Effect-Based Testing and Its Applications
Scientists have developed a new method to detect steroid abuse in athletes using cell-based tests, which could be the future of anti-doping methods.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Expression of retinoid-X receptors (-Æ,-a,-a) and retinoic acid receptors (-Æ,-a,-a) in normal human skin: an immunohistological evaluation
RXR and RAR proteins in skin may help with cell growth, hair growth, and gland function.
research 5α-Reductase, an enzyme regulating glucocorticoid action in the testis of Rhinella arenarum (Amphibia: Anura)
5α-Reductase helps regulate hormone action in toad testes, especially during breeding season.
research Major role for 5-alpha reductase inhibitors in the aging male
5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
research Epigenetic regulation of 5α reductase-1 underlies adaptive plasticity of reproductive function and pubertal timing
Environmental factors affect reproductive traits by altering the SRD5A1 gene.
research HtrA1L364P leads to cognitive dysfunction and vascular destruction through TGF‐β/Smad signaling pathway in CARASIL model mice
The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
research 5α‐reductase inhibitors: Evaluation of their potential confounding effect on GC‐C‐IRMS doping analysis
5α-reductase inhibitors can interfere with doping tests by masking banned substances.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research SRD5A2 and emerging therapies in androgen-driven disorders
research Alopecia areata incognita: a comment
The author clarified that Alopecia Areata Incognita (AAI) and diffuse Alopecia Areata (AA) are different conditions and the case discussed was actually AA, not AAI.
research Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis
ALRV5XR is the most effective hair regrowth treatment at 24 weeks.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.